Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Generic Addiction Rehabilitation Drugs Regain Spotlight With Increased Coverage In Media Outlets

|Includes: BioCorRx Inc. (BICX)

Addiction rehabilitation drugs naltrexone and acamprosate take center stage again as big media corporations like CNN and The New York Times published stories about them. The media attention came following the publication of a recent analysis stating that only 10 percent of addicts were prescribed medications to address their alcohol dependence. The finding was a result of an analysis of over 120 research studies and was published on the Journal of the American Medical Association.

According to The Fix, the analysis collected information from studies involving 23,000 patients treated for alcohol dependency. The studies zeroed in on patients on naltrexone or acamprosate, which were found more effective than other drugs in keeping alcoholics sober. The Fix added that both were particularly helpful in keeping the number of days alcoholics relapse low.

Unfortunately, only few health care practitioners are aware the drugs even exist. "People just don't know about it," said National Institute on Alcohol Abuse and Alcoholism's Division of Treatment and Recovery Research associate director Dr. Raye Litten, The Fix reported. "Many primary care just don't know about this," he told The Fix.

Naltrexone is an opioid receptor antagonist which blocks the euphoric high that addicts get from alcohol and opioid intake. The drug is also known under the brand names Vivitrol and ReVia, according to The New York Times. It usually comes in tablet forms, although biotechnology companies like BioCorRx Inc. (OTCQX: BICX) have started to incorporate and use it in an implant form for its rehabilitation program for alcoholics. BioCorRx Inc. uses a biodegradable, time-release implant that is embedded under the patient's skin and slowly releases naltrexone into the patient's bloodstream.

MedlinePlus describes acamprosate as an alcohol craving inhibitor and as a corrective drug. The website added that the drug changes the brain's mechanism to prevent a person to drink alcohol again, although it doesn't prevent withdrawal symptoms from drinking cessation. According to The New York Times' alcoholism medication guide, acamprosate is more commonly known under the brand name Campral.

Acamprosate works by preventing the transmission of a neurotransmitter called gamma aminobutyric acid (OTC:GABA), which plays a role in inducing alcohol cravings, according to the medication guide. The New York Times notes that acamprosate successfully limits drinking frequency, and is more effective with psychotherapy or combination therapy with naltrexone or disulfiram, an alcohol aversion drug that causes uncomfortable side-effects for the alcoholic when he or she drinks.

BioCorRx Inc. is a leader in addiction rehabilitation in the United States. The company established a name in the alcohol addiction rehabilitation niche following the success of its Start Fresh Program. Since 2013, the company has managed to secure several licensee and distribution agreements for its Start Fresh Program with rehabilitation groups in Atlanta, Georgia, Washington D.C., Maryland, Virginia, and San Francisco, California, to name a few.

BioCorRx Inc. has been heavily promoting its program which includes a Naltrexone implant in media outlets and is most of the time represented by Dr. George Fallieras, medical director of Start Fresh Recovery. Fallieras recently appeared on the hit TV Show, The Doctors, along with a patient and Start Fresh Program life coach and former Growing Pains star Jeremy Miller, to discuss how the Start Fresh Program works and how Naltrexone is a crucial part of the program.